Emerging in the landscape of obesity therapy, retatrutide presents a distinct approach. Unlike many existing medications, retatrutide works as a double agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) sensors. The concurrent engagement promotes various helpful effects, like impr